Matthew Cohen is a Managing Partner at Osage University Partners (OUP), a venture capital firm. See sector focus and contact routes.
Matthew Cohen is a Managing Partner at Osage University Partners (OUP), a venture capital firm, where he joined in 2013 and co-manages the firm’s life science investment activities alongside Bill Harrington, M.D.. His investment thesis focuses on therapeutics, diagnostics, medical devices, and research tools, primarily sourcing cutting-edge technologies from university research. While specific check sizes and lead/follow behavior are not publicly detailed, Cohen oversees and approves all Partnership investments as part of his managing partner responsibilities. Notable portfolio companies he has been involved with include Biohaven Pharma (NYSE: BHVN), Synthorx (acquired by Sanofi), Kura Oncology (NASDAQ: KURA), and Sana Biotechnology (NASDAQ: SANA). Cohen holds a Ph.D. in Cell and Molecular Biology from the University of Pennsylvania and previously worked as a strategy consultant at L.E.K. Consulting serving biopharma and private equity clients. He currently sits on the boards of Coho Therapeutics and IMMvention Therapeutix and serves as a board observer at Arrakis Therapeutics and Faraday Pharma. No distinctive public writing or unique point of v
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Bala Cynwyd.
Investors like Matthew Cohen · Full investor directory · Investor access · Company funding database